Disodium Etidronate

Disodium Etidronate is a bisphosphonate, inhibits bone resorption and thus reduces bone turn over. Disodium Etidronate is used in the treatment of bone disorders in which excessive bone resorption is a problem, such as Paget's disease of bone and osteoporosis. Disodium Etidronate is also used as an adjunct in severe hypercalcemic conditions especially associated with malignancies.

Disodium Etidronate is primarily indicated in conditions like Osteoporosis, Paget's disease of bone, Sedation with amnesia, Severe hypercalcemia.

Disodium Etidronate is contraindicated in conditions like Pregnancy,Breast feeding,Pain and inflammation (rheumatic disease), Vasomotor symptoms in estrogen deficiency.

The incidence of gastrointestinal complaints (diarrhea, nausea) is the same for etidronate disodium at 5 mg/kg/day as for placebo, about 1 patient in 15. At 10 to 20 mg/kg/day the incidence may increase to 2 or 3 in 10. These complaints are often alleviated by dividing the total daily dose.

Disodium Etidronate should be used with caution in renal impairment (reduce dose in mild, avoid if moderate to severe). MONITORING: Serum phosphate, serum alkaline phosphatase and (if possible) urinary hydroxyproline should be measured before starting and at intervals of 3 months---consult product literature for further information. COUNSELLING: Avoid food for at least 2 hours before and after oral treatment particularly calcium-containing products e.g., milk; also avoid iron and mineral supplements and antacids.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

20 mg/kg/day (20 (20)) As recommended. PO — Heterotopic Ossification from Spinal Cord Injury: This dose is given for 2 wk followed by 10 mg/kg/day for 10 wk. Total treatment period is 12 wk. 5 to 10 mg/kg/day (7.5 (7.5)) 24 hourly PO — For paget disease: Dose should not to exceed 6 mo.For retreatment, initiate only after etidronate-free period of at least 90 days and if there is evidence of active disease. Scraped Dose — Clinical experience with acute etidronate disodium overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18 year old female who ingested an estimated single dose of 4000 mg to 6000 mg (67 to 100 mg/kg) of etidronate disodium was reported to be mildly hypocalcemic (7.52 mg/dL) and experienced paresthesia of the fingers. Hypocalcemia resolved 6 hours after lavage and treatment with intravenous calcium gluconate. A 92 year old female who accidentally received 1600 mg of etidronate disodium per day for 3.5 days experienced marked diarrhea and required treatment for electrolyte imbalance. Orally administered etidronate disodium may cause hematologic abnormalities in some patients (see ADVERSE REACTIONS ). Etidronate disodium suppresses bone turnover and may retard mineralization of osteoid laid down during the bone accretion process. These effects are dose and time dependent. Osteoid which may accumulate noticeably at doses of 10 to 20 mg/kg/day of chronic, continuous dosing mineralizes normally post therapy. Prolonged continuous treatment (chronic overdosage) has been reported to cause nephrotic syndrome and fracture. Gastric lavage may remove unabsorbed drug. Standard procedures for treating hypocalcemia, including the administration of Ca ++ intravenously, would be expected to restore physiologic amounts of ionized calcium and relieve signs and symptoms of hypocalcemia. Such treatment has been effective.

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy. The majority of these reports concerned variable elevations in prothrombin times without clinically significant sequelae. Although the relevance of these reports and any mechanism of coagulation alterations is unclear, patients on warfarin should have their prothrombin time monitored.

No storage information is recorded for this medicine yet.